Surgical Strategy and Clinical Outcome in Patients with Bronchial Carcinoids.
Bronchial carcinoid
Clinical outcome
Neuroendocrine neoplasm
Surgical strategy
Survival
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2022
2022
Historique:
pubmed:
23
9
2021
medline:
5
4
2022
entrez:
22
9
2021
Statut:
ppublish
Résumé
Carcinoids are malignant neuroendocrine neoplasms showing good long-term survival after oncologic therapy. The study evaluated the influence of operative strategies and individual decision-making on the outcome and long-term survival in 222 patients with bronchial carcinoids. The patients underwent preoperative pulmonary function tests and bronchoscopy to facilitate surgical decision-making. A hundred and twelve tumors were detected endoscopically, including 32 in the main and lobar bronchi. We performed 5 isolated bronchus resections, 4 segmentectomies, 15 wedge resections, 10 pneumonectomies, 19 sleeve resections, 26 bilobectomies, 138 lobectomies, and 2 chest wall resections. Three patients were technically inoperable. Systematic mediastinal lymphadenectomy was routinely performed although most patients' computer tomography scans showed N0. A hundred and sixty-two patients had typical (155 N0, 7 N+) and 60 patients had atypical carcinoids (39 N0, 21 N+). There was no intraoperative mortality. The hospital mortality was below 2%. Overall, 1-, 5-, and 10-year survival rates were 99%, 94%, and 89%, respectively, in typical carcinoids. Atypical carcinoids show similar 1- and 5-year survival rates, but the 10-year survival rate was below 70%, decreasing in higher N-stages. The N-stage was the most important survival factor. In conclusion, bronchial carcinoids should be surgically treated the way lung cancer is. Anatomic resection and systematic lymphadenectomy are the treatments of choice. The availability of bronchoplastic techniques and preoperative assessment is essential for individual decision-making, focusing predominantly on postoperative quality of life.
Identifiants
pubmed: 34550557
doi: 10.1007/5584_2021_668
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
17-25Informations de copyright
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Références
Arrigoni MG, Woolner LB, Bernatz PE (1972) Atypical carcinoid tumor of the lung. J Thorac Cardiovasc Surg 64:413–421
doi: 10.1016/S0022-5223(19)39836-8
Aubry MC, Thomas CF Jr, Jett JR et al (2007) Significance of multiple carcinoid tumors and Tumorlets in surgical lung specimens: analysis of 28 patients. Chest 131(6):1635–1643
doi: 10.1378/chest.06-2788
Beasley MB, Brambilla E, Travis WD (2005) The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 40(2):90–97
doi: 10.1053/j.ro.2005.01.001
Davies SJ, Gosney JR, Hansell DM, Wells AU, du Bois RM, Burke MM, Sheppard MN, Nicholson AG (2007) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease. Thorax 62(3):248–252
doi: 10.1136/thx.2006.063065
Filosso PL, Rena O, Donati G, Casadio C, Ruffini E, Papalia E, Oliaro A, Maggi G (2002) Bronchial carcinoid tumors: surgical management and long–term outcome. J Thorac Cardiovasc Surg 123(2):303–309
doi: 10.1067/mtc.2002.119886
Fink G, Krelbaum T, Yellin A, Bendayan D, Saute M, Glazer M, Kramer MR (2001) Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 119(6):1647–1651
doi: 10.1378/chest.119.6.1647
Froudarakis M, Fournel P, Burgard G, Bouros D, Boucheron S, Siafakas NM, Emonot A (1996) Bronchial carcinoids. A review of 22 cases. Oncology 53(2):153–158
doi: 10.1159/000227552
Gosain R, Mukherjee S, Yendamuri SS, Iyer R (2018) Management of typical and atypical pulmonary carcinoids based on different established guidelines. Cancers (Basel) 10(12):510
doi: 10.3390/cancers10120510
Gosney JR (2004) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia as a precursor to pulmonary neuroendocrine tumors. Chest 125(5 Suppl):108S
doi: 10.1378/chest.125.5_suppl.108S
Lim E, Goldstraw P, Nicholson AG, Travis WD, Jett JR, Ferolla P, Bomanji J, Rusch VW, Asamura H, Skogseid B, Baudin E, Caplin M, Kwekkeboom D, Brambilla E, Crowley J (2008) Proceedings of the IASLC international workshop on advances in pulmonary neuroendocrine tumors 2007. J Thorac Oncol 3(10):1194–1201
doi: 10.1097/JTO.0b013e3181861d7b
Luckraz H, Amer K, Thomas L, Gibbs A, Butchart EG (2006) Long term outcome of bronchoscopically resected endobronchial typical carcinoid tumors. J Thorac Cardiovasc Surg 132(1):113–115
doi: 10.1016/j.jtcvs.2006.01.061
Quaedvlieg PF, Visser O, Lamers CB, Janssen–Heijen ML, Taal BG (2001) Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol 12(9):1295–1300
doi: 10.1023/A:1012272314550
Rugge M, Fassan M, Clemente R, Rizzardi G, Giacomelli L, Pennelli G, Mescoli C, Segat D, Rea F (2008) Bronchopulmonary carcinoid: phenotype and long–term outcome in a single–institution series of Italian patients. Clin Cancer Res 14(1):149–154
doi: 10.1158/1078-0432.CCR-07-1631
Schreurs JM, Westermann CJ, Van der Bosch JM, Vanderschueren RG, Brutel de la Rivière A, Knaepen PJ (1992) A twenty–five follow–up of ninety–three resected typical carcinoid tumors of the lung. J Thorac Cardiovasc Surg 104(5):1470–1475
doi: 10.1016/S0022-5223(19)34645-8
Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, Koss MN (1998) Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22(8):934–944
doi: 10.1097/00000478-199808000-00003
Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E (1999) Histological typing of lung and pleural tumours. Springer, Berlin/Heidelberg
doi: 10.1007/978-3-642-60049-4
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (2015) Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol 10(9):1240–1242
doi: 10.1097/JTO.0000000000000663
Zell JA, Ou SH, Ziogas A, Anton–Culver H (2005) Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol 23(33):8396–8405
doi: 10.1200/JCO.2005.03.0312